Related Experiment Video

Updated: May 26, 2026

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
07:15

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

PPARγ as a therapeutic target in diabetic nephropathy and other renal diseases

Jichun Yang1, Yunfeng Zhou, Youfei Guan

  • 1Department of Physiology and Pathophysiology, Peking (Beijing) University Diabetes Center, Key Laboratory of Molecular Cardiovascular Sciences, Peking (Beijing) University Health Science Center, Beijing, China.

Current Opinion in Nephrology and Hypertension
|December 7, 2011
PubMed
Abstract

Insights

Peroxisome proliferator-activated receptor gamma (PPARγ) agonists show protective effects against various kidney diseases, particularly diabetic nephropathy. These findings highlight PPARγ as a potential therapeutic target for renal disease treatment.

Area of Science:

  • Nephrology
  • Endocrinology
  • Molecular Biology

Background:

  • Peroxisome proliferator-activated receptor gamma (PPARγ) is a nuclear transcription factor regulating key physiological processes.
  • PPARγ influences glucose and lipid metabolism, energy homeostasis, inflammation, and cell proliferation.

Purpose of the Study:

  • To review recent findings on the protective effects of PPARγ against kidney diseases.
  • To focus on the role of PPARγ in diabetic nephropathy.
  • To explore the underlying mechanisms of PPARγ's renoprotective actions.

Main Methods:

  • Literature review of recent studies on PPARγ and kidney diseases.
  • Analysis of experimental and clinical data evaluating PPARγ agonists.
  • Synthesis of information on mechanisms of action.

Main Results:

  • PPARγ agonists demonstrate protective effects in diverse kidney diseases, including diabetic nephropathy, ischemic injury, IgA nephropathy, and polycystic kidney disease.
  • These benefits are mediated through both systemic and local renal actions.
  • PPARγ plays a significant role in both normal kidney function and disease states.

Conclusions:

  • PPARγ agonists can delay or prevent the progression of numerous renal diseases, with a notable impact on diabetic nephropathy.
  • PPARγ emerges as a promising therapeutic target for managing kidney diseases.
  • Further research into PPARγ modulation could lead to novel treatment strategies for renal pathologies.

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
G Protein-coupled Receptors01:15

G Protein-coupled Receptors

G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
Diabetic Nephropathy01:28

Diabetic Nephropathy

Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...